Gene Reports is a prominent academic journal published by Elsevier that focuses on the rapidly evolving field of genetics. Launched in 2015, this journal serves as a pivotal platform for the dissemination of cutting-edge research, bridging the gap between basic and applied genetics studies. Although it currently holds a Q4 ranking in the Genetics category and stands at the 248th position out of 347 in Scopus rankings, its potential for growth is significant given the increasing interest in genetic research across various disciplines. With an E-ISSN of 2452-0144, Gene Reports aims to provide open access to original research articles, reviews, and short communications that advance the collective understanding of genetic mechanisms and their applications. As a publication that continues to shape the future of genetics, it is an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in this crucial field.

INTERNATIONAL JOURNAL OF HUMAN GENETICS is a distinguished publication dedicated to advancing knowledge in the fields of genetics and molecular biology. Published by KAMLA-RAJ ENTERPRISES, this journal explores critical developments and research findings from 2008 to 2016, though its coverage in Scopus has since been discontinued. With an ISSN of 0972-3757 and an E-ISSN of 2456-6330, the journal aimed to foster scholarly dialogue and serve as a resource for researchers, professionals, and students engaged in human genetics. While the journal holds a modest ranking in categories such as Biochemistry and Genetics, it remains a vital source for exploring niche topics within the realm of human genetics. Researchers interested in genetic screening, gene therapy, and clinical genetics will find valuable insights herein. Despite its pause in indexing, the journal continues to contribute to the academic discourse by disseminating critical research that bridges gaps in understanding human genetics.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

GENE THERAPY, published by SpringerNature, is a prestigious academic journal at the forefront of research in the fields of genetics, molecular biology, and molecular medicine. Since its inception in 1994, this journal has evolved into a vital resource for scholars, practitioners, and students, providing cutting-edge insights into gene therapy techniques and innovations. With an impressive impact factor reflecting its significant influence— ranking in the Q1 quartile across multiple categories in 2023—GENE THERAPY offers rigorous peer-reviewed articles that address both basic and applied aspects of gene therapy. The journal is recognized for its role in promoting advancements in therapeutic strategies, thus enhancing understanding of genetic disorders and treatment efficacy. Researchers will find this journal invaluable for publishing their findings, staying updated on the latest breakthroughs, and fostering interdisciplinary collaborations. Engage with the latest in gene therapy by accessing this influential platform, and contribute to a field that holds the potential to transform healthcare outcomes worldwide.

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Molecular Oncology, published by WILEY, is a premier open-access journal that has been at the forefront of cancer research since its inception in 2007. With an impressive impact factor reflective of its outstanding contribution to the field, it holds a prestigious position in the Q1 category across multiple disciplines, including Cancer Research, Genetics, and Molecular Medicine. This journal is essential for researchers and professionals seeking to publish high-quality findings in a rapidly evolving area of study, underscored by its significant Scopus rankings that place it within the top percentiles of Oncology and Molecular Biology. As an open-access journal since 2017, it ensures that vital research is readily available to a global audience, thereby facilitating collaboration and knowledge dissemination among academic and clinical communities. With its commitment to innovative and impactful research, Molecular Oncology continues to be a critical resource for advancing our understanding of cancer biology and treatment.

MUTAGENESIS, published by Oxford University Press, is a leading journal in the fields of genetics, toxicology, and health, dedicated to advancing our understanding of mutagenic processes and their implications for human health. With an ISSN of 0267-8357 and an E-ISSN of 1464-3804, this journal has been at the forefront of mutagenesis research since its inception in 1986 and will continue to publish cutting-edge studies until 2024. Holding an impressive position in the academic community, MUTAGENESIS is ranked Q2 in Genetics, Q2 in Clinical Genetics, Q2 in Health, Toxicology, and Mutagenesis, and Q1 in Toxicology, reflecting its commitment to high-quality scholarly work. The journal enjoys a robust global readership, with significant rankings in various Scopus categories, including top positions in Environmental Science and Clinical Genetics, ensuring that it remains a vital resource for researchers, professionals, and students alike. While access to its articles is not completely open, MUTAGENESIS provides valuable insights that fuel innovative research and drive forward the understanding of genetic risks and toxicological assessments.